SRPT Tshuag Surges Rau Muaj Peev Xwm Ceev Pom Zoo Rau Kev Kho Mob

Lub Chaw Tswj Xyuas Khoom Noj thiab Tshuaj tau hais rau hnub Monday nws yuav ua qhov kev tshuaj xyuas sai Sarepta Tshuaj Kho Mob'((SRPT) leeg nqaij dystrophy noob kho, thiab SRPT Tshuag dhia.




X



Sarepta tau thov kev pom zoo raws li peb qhov kev tshawb fawb soj ntsuam ntawm kev kho noob, SRP-9001. Tab sis ib txoj kev tshawb nrhiav, hu ua Embark, tseem tab tom ua tiav nrog cov txiaj ntsig xav tau los ntawm qhov kawg ntawm 2023. FDA yuav txiav txim siab pom zoo ua ntej cov txiaj ntsig tau tshwm sim hauv lub Tsib Hlis. Qhov no txhais tau tias Sarepta tuaj yeem tso cov tshuaj ntxov ua ntej nws muaj qhov kawg ntawm tes los ntawm cov txheej txheem hu ua kev pom zoo nrawm.

"Hauv qhov zoo tshaj plaws, qhov no yuav nrawm '9001 lub sijhawm rau kev lag luam," RBC Capital Markets kws tshuaj ntsuam Brian Abrahams tau hais hauv tsab ntawv ceeb toom rau cov neeg siv khoom. Kev pom zoo nrawm yog ib txwm muaj raws li kev tshawb fawb pom tseeb. Embark tuaj yeem dhau los ua qhov ntawd, cov kws tshuaj ntsuam tau hais.

Nyob rau Tshuag lag luam hnub no, SRPT Tshuag tau nce 3.1% siab dua, xaus qhov kev sib tham tsis tu ncua ntawm 118.13. Sarepta Tshuag muaj zog Ntsuam Xyuas Lub Zog Muaj Zog ntawm 96, uas tso nws nyob rau saum 4% ntawm tag nrho cov stocks nyob rau hauv cov nqe lus ntawm 12-lub hlis kev ua tau zoo, raws li IB Digital.

SRPT Tshuag: Hloov Ib Lub Neej Tsis Zoo

Cov neeg mob nrog Duchenne cov leeg nqaij dystrophy nqa ib qho txawv txav ntawm lub luag haujlwm ua rau cov protein dystrophin. Dystrophin yog qhov tseem ceeb rau cov leeg mob thiab kev ua haujlwm. Sarepta's gene therapy aims mus ntxig cov noob kho uas cov lej rau luv luv version ntawm dystrophin protein.

Cov kws tshuaj ntsuam xav tias FDA yuav teem sijhawm lub rooj sib tham pawg neeg tawm tswv yim los tham txog cov txiaj ntsig thiab kev pheej hmoo ntawm Sarepta's gene therapy. Yog tias muaj, cov kws pab tswv yim yuav ua ib qho kev pom zoo rau lub koom haum tag nrho.

Tseem, cov xov xwm hnub Monday "ib feem ntawm kev pheej hmoo Sarepta, muab cov tub ua lag luam tau nug txog qhov muaj feem cuam tshuam ntawm FDA pom zoo rau lub sijhawm nrawm nrog txoj kev tshawb fawb Embark tau nyob ze tom qab," Needham tus kws tshuaj ntsuam Gil Blum tau hais hauv tsab ntawv tshaj tawm.

Nws muaj qhov kev yuav khoom thiab 158 tus nqi phiaj ntawm SRPT Tshuag.

Ua raws li Allison Gatlin ntawm Twitter ntawm @IBD_AGatlin.

KOJ UA LI CAS:

Biogen Dives Ntawm Cov Lus Qhia Txog Kev Tuag Alzheimer Thaum Axsome Soars Ntawm Nws Txoj Kev Kawm Ua tiav

IBD Tshuag Ntawm Hnub Catalyst Pharma yog Hinting Ntawm Kev Tau Txais - Vim Li Cas Lub Sijhawm Zoo Kawg

Yuav Tshawb Fawb Txog Kev Loj Hlob Cov Dab Tsi: Vim Li Cas Qhov Cuab Yeej IBD no Yooj Yim Siv Kev Tshawb Xyuas Txog Cov Khoom Loj

Pom Cov Txiaj Ntsig Zoo Li Qub Nrog MarketSmith Txawv Cov Qauv Cim & Cov Duab Ntsej Muag

Nrhiav Kom Tom Ntej Kua Los Yog Amazon? Pib Nrog Cov S&P 500-Npav Npe

Tau qhov twg los: https://www.investors.com/news/technology/srpt-stock-surges-on-potential-accelerated-approval-for-gene-therapy/?src=A00220&yptr=yahoo